Investigation of the antibacterial activity of 3-O-octanoyl-(−)-epicatechin

T.P.T. Cushnie1, P.W. Taylor2, Y. Nagaoka3, S. Uesato3, Y. Hara4 and A.J. Lamb1

1 School of Pharmacy, The Robert Gordon University, Schoolhill, Aberdeen, UK
2 Microbiology Group, School of Pharmacy, University of London, London, UK
3 Faculty of Chemistry, Materials and Bioengineering, Kansai University, Suita, Osaka, Japan
4 Mitsui Norin Co. Ltd, Minato-Ku, Tokyo, Japan

Abstract

Aims: To measure antibacterial activity of the semi-synthetic flavonoid 3-O-octanoyl-(−)-epicatechin and investigate the mechanism of action.

Methods and Results: MICs determined by the broth microdilution method were 50 μg ml−1 for β-lactam sensitive and resistant Staphylococcus aureus, and 100 μg ml−1 for vancomycin sensitive and resistant enterococci. In time-kill studies, 100 μg ml−1 3-O-octanoyl-(−)-epicatechin reduced colony forming unit numbers of antibiotic sensitive and methicillin-resistant Staph. aureus below detectable levels within 120 min. Bacterial aggregation was not observed when cells exposed to 3-O-octanoyl-(−)-epicatechin were examined by light microscopy. It was also shown that 50 μg ml−1 3-O-octanoyl-(−)-epicatechin is capable of reducing colony forming unit numbers of high cell density Staph. aureus populations by 80-fold within 60 min incubation, and inducing leakage of 50% of their internal potassium within just 10 min.

Conclusions: 3-O-Octanoyl-(−)-epicatechin is active against Gram-positive bacteria, has bactericidal activity against both antibiotic sensitive and resistant strains, and is likely to exert its primary antibacterial effect by damaging the cytoplasmic membrane.

Significance and Impact of the Study: 3-O-Octanoyl-(−)-epicatechin has significant antibacterial activity and additional structural modification and/or formulation studies may allow this to be potentiated.

Introduction

The emergence and spread of antibiotic-resistant bacteria such as vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) is a cause for serious concern (Croft et al. 2007). MRSA, in particular, is being seen with increasing prevalence in many parts of the world (Gould 2005), and the recent discovery of vancomycin resistance among such strains (Schwaber et al. 2003) is a stark reminder of the almost limitless capacity that bacteria have for adaptation and survival. In the past, medicine and science were able to stay one step ahead of the resistance problem through the discovery of potent new classes of antimicrobial agent, but this process has slowed to a virtual standstill since the 1970s and the pipeline of new drugs is running dry (IDSA 2004; Croft et al. 2007). Given that it takes between 12 and 15 years for the development of new agents (Watkins 2002), considerable efforts in this area of research are now urgently required.

In a recent report by the World Health Organization (WHO), it was estimated that 25% of modern medicines have been derived from plants that were first used in traditional medicine (WHO 2003). Flavonoids are a group of phytochemicals with a rich history of use in the treatment of human diseases, and are increasingly becoming the subject of medical research (Havsteen 2002; Cushnie and Lamb 2005a). Compounds of the flavan-3-ol (or

Keywords

antibacterial, bactericidal, catechin, cytoplasmic membrane, flavonoid, flavan-3-ol, octanoyl.
catechin) class are found at high concentrations in woody plants such as *Camellia sinensis* (Japanese green tea; Daniel 2005; Taylor et al. 2005) and *Elaeagnus glabra* Thunb. (an Okinawan shrub used in medicine; Nishino et al. 1987), and have been reported to possess antibacterial activity on numerous occasions (Taguri et al. 2004; Taylor et al. 2005; Friedman 2007). Several research groups have postulated that the mechanism of action underlying this activity involves an interaction between the catechins and the cytoplasmic membrane (Ikigai et al. 1993; Tsuchiya 1999; Caturla et al. 2003).

The incorporation of fatty acid hydrocarbon chains into certain compounds is known to increase their propensity to interact with lipid bilayers, and in the past this strategy has successfully been used to increase the antibacterial activity of the human peptide, cathepsin G (Mak et al. 2003). Working on the hypothesis that catechins target the bacterial membrane, and with the intention of improving the ability of catechins to interact with this cell structure, a number of 3-O-acyl derivatives were synthesised. Subsequent analysis indicated that 3-O-octanoyl-(–)-epicatechin (Fig. 1) has superior anti-MRSA activity to the naturally occurring flavonoid (–)-epicatechin and its acylated derivative 3-O-octanoyl-(–)-epicatechin gallate, and it was suggested that this acyl derivative and some of its structural relatives may be useful as topical therapeutic agents (Stapleton et al. 2004). The purpose of the present investigation was to ascertain the range of bacteria against which 3-O-octanoyl-(–)-epicatechin is effective. In addition, time-kill assays and agglutination studies were performed to determine whether or not the agent has bactericidal properties, and potassium loss assays were conducted to establish cytoplasmic membrane damage as the primary antibacterial mechanism of action.

**Materials and methods**

**Chemicals**

Cephalosporin C (potassium salt; ~90%), dimethylsulphoxide (DMSO), (–)-epicatechin, novobiocin (sodium salt; minimum 90%), phosphate buffered saline (PBS; pH 7.4) tablets, penicillin G and sodium octanoate were obtained from Sigma (Sigma-Aldrich Co. Ltd, Poole, UK). In addition, n-glucose monohydrate and sodium chloride (general purpose grade) were from Fisher Scientific UK Ltd (Loughborough, UK), ethanol was from Hayman Ltd (Witham, UK), Iso-sensitest nutrient broth and agar were from Oxoid Ltd (Basingstoke, UK), and vancomycin hydrochloride hydrate and galangin were from Aldrich (Sigma-Aldrich Co. Ltd, Gillingham, UK).

**Bacteria**

Strains of bacteria (listed in Table 1 along with corresponding phenotype) were obtained from the National Collection of Type Cultures (NCTC, London, UK), the American Type Culture Collection (ATCC, Manassas, VA, USA) and the National Collections of Industrial, Food and Marine Bacteria (NCIMB, Aberdeen, UK). At least one antibiotic sensitive and two antibiotic-resistant strains of each species were selected for testing, and these were subcultured and maintained on agar as described previously (Cushnie et al. 2003). All of the bacteria used in experiments in the present investigation were prepared in broth, harvested after 18 h incubation at 37°C, and washed and resuspended in aqueous 0.9% (w/v) sodium chloride (Cushnie et al. 2003).

**MIC determinations using the broth microdilution assay**

Assays were performed in 96-well microtitre trays (gamma-irradiated; Bibby Sterilin Ltd, Stone, UK) with an inoculum density of $\sim 5 \times 10^5$ CFU ml$^{-1}$ in 100 µl of broth. In the experiments carried out to assess activity of the catechins and sodium octanoate, positive control wells containing broth supplemented with solvent only [1% (v/v) ethanol] were included. All commercial antibacterial agents were dissolved in sterile distilled water without the aid of additional solvents. Negative control wells containing an uninoculated dilution series of test agent and broth were included in all experiments. MICs were obtained after trays had been incubated at 37°C for 18 h (Mark II proportional temperature controller; LEEC Ltd, Nottingham, UK). Experiments were performed in duplicate to confirm the reproducibility of results.

**Figure 1** The structure of (–)-epicatechin and its acylated derivative 3-O-octanoyl-(–)-epicatechin.
**Table 1** The MICs of 3-O-octanoyl-(-)-epicatechin and its component structures [(-)-epicatechin and octanoate] against a selection of antibiotic sensitive and antibiotic-resistant Gram-positive and Gram-negative bacteria

| Bacterial strain         | Phenotype                                | Penicillin G | Vancomycin | Cephalosporin C | 3-O-oct-(-)-EC | (-)-EC | Sodium octanoate |
|-------------------------|------------------------------------------|--------------|------------|-----------------|----------------|-------|-----------------|
| Staph. aureus NCTC 6571 | Antibiotic sensitive                     | 0.0156       | ND         | ND              | 50             | –     | –               |
| Staph. aureus NCTC 10788| Antibiotic sensitive                     | 0.0078       | ND         | ND              | 50             | –     | –               |
| Staph. aureus NCTC 11940| Methicillin resistant                    | 32           | ND         | ND              | 50             | –     | –               |
| Staph. aureus ATCC 33591| Methicillin resistant                    | 32           | ND         | ND              | 50             | –     | –               |
| Staph. aureus NCTC 11561| β-Lactamase producing                    | 128          | ND         | ND              | 50             | –     | –               |
| Staph. aureus NCIMB 9968| Resistant to penicillin, streptomycin and tetracycline | 64           | ND         | ND              | 50             | –     | –               |
| Ent. faecalis NCIMB 775 | Antibiotic sensitive                     | ND           | 0.5        | ND              | 100            | –     | –               |
| Ent. faecalis NCTC 12201| Vancomycin resistant                     | ND           | 256        | ND              | 100            | –     | –               |
| Ent. faecalis NCTC 12203| Vancomycin resistant                     | ND           | 256        | ND              | 100            | –     | –               |
| Ent. faecium NCTC 7171 | Antibiotic sensitive                     | ND           | 1.0        | ND              | 100            | –     | –               |
| Ent. faecium NCTC 12202| Vancomycin resistant                     | ND           | 256        | ND              | 100            | –     | –               |
| Ent. faecium NCTC 12204| Vancomycin resistant                     | ND           | 256        | ND              | 100            | –     | –               |
| E. coli NCTC 12241     | Antibiotic sensitive                     | 50           | ND         | ND              | –              | –     | –               |
| E. coli NCTC 11954     | β-Lactamase producing                    | 80           | ND         | ND              | –              | –     | –               |
| E. coli NCTC 11560     | β-Lactamase producing                    | 1600         | ND         | ND              | –              | –     | –               |
| Ps. aeruginosa NCTC 10662| Antibiotic sensitive                    | ND           | ND         | 1600            | –              | –     | –               |
| Ps. aeruginosa NCTC 8203| Cephalosporinase producing              | ND           | ND         | 1600            | –              | –     | –               |
| Ps. aeruginosa NCTC 8506| Cephalosporinase & streptomycin antagonist producing | ND           | 3200       | –               | –              | –     | –               |

3-O-oct-(-)-EC, 3-O-octanoyl-(-)-epicatechin; (-)-EC, (-)-epicatechin; ND, not determined; –, no antibacterial activity detected at concentrations up to and including 200 μg ml⁻¹.

**Time-kill studies**

Two control flasks were prepared by pipetting either 20 ml broth or 20 ml broth supplemented with 1% (v/v) ethanol into sterile glass flasks. A third sterile glass flask, containing 20 ml broth supplemented with the desired concentration of 3-O-octanoyl-(-)-epicatechin and 1% (v/v) ethanol, was prepared after bacterial harvest, washing and enumeration. Flasks were then inoculated so as to contain ~5 × 10⁵ CFU ml⁻¹ of test bacterium and incubated at 37°C in an orbital incubator set at 100 rev min⁻¹ (IOX400.XX2.C; Sanyo Gallenkamp PLC, Loughborough, UK). Colony forming unit counts were performed for each suspension after various time intervals by removing 0.1 ml samples, preparing a dilution series in PBS (10⁻¹–10⁻⁹) and plating out this dilution series (ten 20 μl drops per dilution) on agar. Experiments were performed in duplicate to confirm the reproducibility of results.

**Examination of 3-O-octanoyl-(-)-epicatechin treated bacteria for aggregation**

In this section of work, 3-O-octanoyl-(-)-epicatechin treated *Staph. aureus* cells were examined by light microscopy to establish if results from time-kill studies were attributable to bacterial killing, bacterial aggregation or a combination of both. Preparatory experiments involved performing time-kill assays with ~5 × 10⁷ CFU ml⁻¹ *Staph. aureus* NCTC 6571 and 3-O-octanoyl-(-)-epicatechin to identify a suitable concentration(s) of agent and an appropriate treatment time. Untreated and 3-O-octanoyl-(-)-epicatechin treated samples were then examined by standard brightfield light microscopy (1000× magnification) as described previously (Cushnie et al. 2007), and representative photographs were taken (Leitz DMR microscope and DMRD camera; Leica UK Ltd, Milton Keynes, UK). Samples treated with MIC levels of the flavonoid galangin were also examined for comparative purposes.

**Detection of cytoplasmic membrane damage in 3-O-octanoyl-(-)-epicatechin treated bacteria**

Potassium leakage was identified as an appropriate means of examining 3-O-octanoyl-(-)-epicatechin treated bacteria for cytoplasmic membrane damage, as this is one of the first signs of an increase in bacterial membrane permeability, and because potassium leakage can be readily measured...
measured over time. In order to identify a suitable concentration of 3-O-octanoyl-(−)-epicatechin with which to treat and examine *Staph. aureus* cells for potassium leakage, time-kill studies were performed with the semi-synthetic flavonoid and ∼1 × 10^9 CFU ml^{-1} *Staph. aureus* NCTC 6571. This involved preparing two sterile glass flasks with 18 ml unsupplemented iso-osmotic [1:96% (v/v)] DMSO and 18 ml iso-osmotic DMSO supplemented with 3-O-octanoyl-(−)-epicatechin, inoculating each of these with 2 ml of ∼1 × 10^{10} CFU ml^{-1} *Staph. aureus* NCTC 6571, incubating at 37°C and 100 rev min^{-1}, and performing colony forming unit counts. Experiments were repeated to verify the reproducibility of results.

The effect of 3-O-octanoyl-(−)-epicatechin upon potassium loss from populations of ∼1 × 10^9 CFU ml^{-1} *Staph. aureus* NCTC 6571 was then investigated. The effects of MIC levels of novobiocin (62.5 ng ml^{-1}) and penicillin G (15.6 ng ml^{-1}), determined using the broth microdilution method, were also examined for comparative purposes. Assays were performed by preparing two sterile polymethylpentene flasks containing 27 ml iso-osmotic DMSO, inoculating these with 2 ml of ∼1:6 × 10^{10} CFU ml^{-1} *Staph. aureus*, shaking the flasks to evenly distribute bacteria and removing two 1 ml samples from each for processing as described previously (Cushnie and Lamb 2005b). Three millilitres of test agent (dissolved in iso-osmotic DMSO and at 10 times the desired final concentration) was then added to the first flask, and 3 ml of unsupplemented iso-osmotic DMSO was added to the second flask, before mixing and removal of another two 1 ml samples for processing. At this point, both flasks were placed into a shaking water bath (Clifton Model NES-28D; Nickel-Electro Ltd, Weston-super-Mare, UK) set to a temperature of 37°C and a speed of 400 (arbitrary units). Two 1 ml samples were removed from each flask every 10 min for 60 min. In order to determine the total potassium pool, flasks were then boiled for 30 min and four 1 ml samples were removed for processing. After all samples had been collected, extracellular potassium concentrations were measured by flame atomic emission spectrophotometry (Model AA3100; Perkin-Elmer Ltd, Beaconsfield, UK) and graphs of percentage potassium loss vs time were plotted. Each assay was performed in duplicate to verify the reproducibility of results.

**Results**

**MIC determinations using the broth microdilution assay**

(−)-Epicatechin showed no activity against any of the 18 test strains when used at concentrations up to and including 200 μg ml^{-1} (Table 1). The acylated derivative of this compound, 3-O-octanoyl-(−)-epicatechin, exhibited inhibitory activity against antibiotic sensitive and resistant strains of *Staph. aureus* and enterococci, but not against Gram-negative bacteria. On its own, the octanate chain exhibited no antibacterial activity at concentrations up to and including 200 μg ml^{-1}.

**Time-kill studies**

In time-kill assays with 50 μg ml^{-1} 3-O-octanoyl-(−)-epicatechin (and an inoculum density of ∼5 × 10^5 CFU ml^{-1}), a 600-fold reduction was seen in numbers of *Staph. aureus* NCTC 6571 colony forming units, and a 1300-fold reduction was seen in *Staph. aureus* NCTC 11940 colony forming unit numbers within 2 h incubation (data not shown). However, bacterial re-growth was seen with both strains with recovery to a level of ∼5 × 10^5 CFU ml^{-1} reached after 24–28 h. Experiments were therefore repeated with the semi-synthetic flavonoid at twice the MIC. At a concentration of 100 μg ml^{-1}, 3-O-octanoyl-(−)-epicatechin reduced colony forming unit numbers of ∼5 × 10^5 CFU ml^{-1} *Staph. aureus* NCTC 6571 and *Staph. aureus* NCTC 11940 by more than 1000-fold in just 60 min (Fig. 2a,b). Within 120 min, colony forming unit numbers of both strains had been reduced below the minimum detectable level (∼50 CFU ml^{-1}). No bacterial re-growth was observed in the 34 h that followed, and colony forming unit numbers in flavonoid treated populations were found to have remained below the minimum detectable level when additional samples were taken after 80 and 168 h (7 days) incubation.

**Examination of 3-O-octanoyl-(−)-epicatechin treated bacteria for aggregation**

At concentrations of 50 and 100 μg ml^{-1}, and within 60 min of incubation, 3-O-octanoyl-(−)-epicatechin reduced colony counts of ∼5 × 10^5 CFU ml^{-1} *Staph. aureus* NCTC 6571 by approximately 800-fold and 165 000-fold, respectively (data not shown). These results suggested that 50 and 100 μg ml^{-1} would be suitable concentrations for the detection of flavonoid-induced aggregation of *Staph. aureus* cells, as they both produced readily detectable decreases in colony counts of bacterial populations. Sixty minutes was selected as the treatment time in order to minimise *Staph. aureus* cell growth and the incidence of naturally occurring clusters in treated and untreated flasks.

In subsequent light microscopy experiments, samples of untreated *Staph. aureus* were found to contain bacteria that were evenly distributed and typically occurring as
single cells, cell pairs and small clusters (Fig. 3a). Samples of *Staph. aureus* that had been incubated with 50 μg ml⁻¹ 3-O-octanoyl-(-)-epicatechin for 60 min had a similar appearance (Fig. 3b). When 100 μg ml⁻¹ 3-O-octanoyl-(-)-epicatechin treated samples were examined, the majority of bacteria were again seen as single cells, cell pairs and small clusters (Fig. 3c). It should be noted that a large amount of detritus (possibly cell debris) was detected in the 100 μg ml⁻¹ 3-O-octanoyl-(-)-epicatechin treated samples though, and it is possible that this prevented observation of all of the treated cells. High levels of aggregation were observed in the positive control samples (Fig. 3d).

Detection of cytoplasmic membrane damage in 3-O-octanoyl-(-)-epicatechin treated bacteria

Experiments in this section of the study were performed using aqueous iso-osmotic DMSO, as *Staph. aureus* cells remained viable for longer in this solution than in aqueous iso-osmotic ethanol. From Fig. 4, it can be seen that populations of ~1 × 10⁹ CFU ml⁻¹ *Staph. aureus* NCTC 6571 underwent an 80-fold reduction in their colony forming unit numbers when incubated in the presence of 50 μg ml⁻¹ 3-O-octanoyl-(-)-epicatechin for 60 min. After 6 h incubation with the semi-synthetic flavonoid, colony forming unit numbers had decreased by 1900-fold. These results indicated that MIC levels of 3-O-octanoyl-(-)-epicatechin were capable of producing a readily detectable effect against high cell densities of *Staph. aureus*, and suggested that it would be possible to perform...
subsequent potassium loss assays using 50 μg ml⁻¹ semi-synthetic flavonoid and 1 × 10⁵ CFU ml⁻¹ *Staphylococcus aureus* NCTC 6571 suspended in an aqueous DMSO medium.

In the experiments that followed, 3-O-octanoyl-(–)-epicatechin was found to induce rapid potassium loss from cells of *Staph. aureus* (Fig. 5a). Flavonoid treatment of *Staph. aureus* populations resulted in leakage of 50% of their total potassium pool within just 10 min. MIC levels of novobiocin and penicillin G, by sharp contrast, induced no increase in potassium loss from populations of ~1 × 10⁸ CFU ml⁻¹ *Staph. aureus* NCTC 6571 during 60 min incubation (Fig. 5b,c). It should be noted that a low level of potassium loss was detected from untreated control populations of *Staph. aureus* throughout this work (Fig. 5a–c). As in the case of the previous study with galangin (Cushnie and Lamb 2005b), this is likely to have occurred as a consequence of starvation-induced autolysis.

**Discussion**

Results from the present investigation show that (–)-epicatechin does not inhibit the growth of *Staph. aureus*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli* or *Pseudomonas aeruginosa* when tested at concentrations up to and including 200 μg ml⁻¹ (Table 1). These results indicate that (–)-epicatechin has negligible antibacterial activity. Importantly however, the acylated derivative of this compound 3-O-octanoyl-(–)-epicatechin was found to have antibacterial activity, inhibiting growth of staphylococcal strains at 50 μg ml⁻¹, and enterococcal strains at 100 μg ml⁻¹. These results are in broad agreement with the previous study, which found that 3-O-octanoyl-(–)-epicatechin has more potent antibacterial activity than (–)-epicatechin gallate (Stapleton et al. 2004). Results presented here also correlate well with those of Mellou et al., who report that acylation of the flavonoid chryssoeriol-7-[6”’-O-acetyl-β-D-allosyl-(1 → 2)-β-D-glucopyranoside] leads to increased antibacterial activity against *Staph. aureus* and *Bacillus cereus* (Mellou et al. 2005). On its own, the octanoate structure is inactive at concentrations up to and including 200 μg ml⁻¹ (Table 1), indicating that 3-O-octanoyl-(–)-epicatechin activity is not attributable to this hydrocarbon chain but a combination of both the (–)-epicatechin and hydrocarbon chain structures. In addition to identifying some of the bacterial species against which 3-O-octanoyl-(–)-epicatechin is effective, results presented in Table 1 show that there is no detectable cross-resistance between 3-O-octanoyl-(–)-epicatechin and either the β-lactams or vancomycin. This finding is important because the existence of cross-resistance between 3-O-octanoyl-(–)-epicatechin and an antibiotic in current use would almost certainly make redundant any plans to try and develop 3-O-octanoyl-(–)-epicatechin as an antibacterial agent.

When populations of antibiotic sensitive and methicillin-resistant *Staph. aureus* were exposed to 100 μg ml⁻¹ 3-O-octanoyl-(–)-epicatechin in time-kill assays, the colony forming unit numbers decreased more than 1000-fold within 60 min of incubation (Fig. 2). Unlike time-kill experiments with galangin (Cushnie et al. 2003), concentrations of treated bacteria remained below detectable levels for the duration of the assays (36 h). Furthermore, no viable colony forming units were recovered from flasks containing 3-O-octanoyl-(–)-epicatechin after 80 h or even 7 days incubation. These results strongly suggest that 3-O-octanoyl-(–)-epicatechin has bactericidal activity. However, given the evidence that natural flavonoids (–)-epigallocatechin gallate (Iki-gai et al. 1993) and galangin (Cushnie et al. 2007) induce substantial clumping of bacterial cells, it was considered prudent to check that decreases in colony forming unit numbers caused by 3-O-octanoyl-(–)-epicatechin were not the result of a similar aggregatory effect.

In subsequent light microscopy studies, samples of *Staph. aureus* NCTC 6571 that had been treated with 50 μg ml⁻¹ (Fig. 3b) and 100 μg ml⁻¹ (Fig. 3c) 3-O-octanoyl-(–)-epicatechin were found to have a similar appearance to those of untreated samples (Fig. 3a). The predominance of single cells, cell pairs and small clusters in 50 and 100 μg ml⁻¹ treated samples indicates that 3-O-octanoyl-(–)-epicatechin does not induce a significant

![Figure 4](image-url) The effect of 3-O-octanoyl-(–)-epicatechin on a population of ~1 × 10⁸ CFU ml⁻¹ *Staphylococcus aureus* NCTC 6571. (■) Aqueous 1:77% (v/v) DMSO and 0.09% (w/v) sodium chloride; (△) 50 μg ml⁻¹ 3-O-octanoyl-(–)-epicatechin, 1:77% (w/v) DMSO and 0.09% (w/v) sodium chloride.
aggregatory effect. These results support the suggestion that 3-O-octanoyl-(−)-epicatechin has bactericidal activity.

Data from Figs 4 and 5a show that 50 μg ml⁻¹ 3-O-octanoyl-(−)-epicatechin is capable of causing an 80-fold reduction in colony counts of \(~1 \times 10^9\) CFU ml⁻¹ *Staphylococcus aureus* NCTC 6571 during 60 min of incubation and inducing substantial potassium loss (approximately 50% of the total pool) within just 10 min. MIC levels of the bacteriostatic antibiotic novobiocin and the bactericidal antibiotic penicillin G (Block and Beale 2004), by comparison, induced no increase in potassium loss from *Staph. aureus* populations during 60 min treatments (Fig. 5b,c). These experiments indicate that 3-O-octanoyl-(−)-epicatechin causes damage to the cytoplasmic membrane of bacteria and strongly suggest that this is the primary antibacterial mechanism of action underlying the semi-synthetic flavonoid’s activity. The absence of novobiocin-induced potassium loss implies that data shown in (Fig. 5a) is not the result of a general emergency response by cells to the presence of an antibacterial agent. Also, the failure of penicillin G to induce potassium loss, and the speed with which 3-O-octanoyl-(−)-epicatechin induces potassium loss, indicates that results in Fig. 5a were not caused by bactericidal agent induced autolysis. Data presented here correlates well with previous research, which showed that structurally related 3-O-octanoyl-(+)-catechin promotes labelling of *Staph. aureus* cells with membrane impermeable propidium iodide (Stapleton et al. 2004). The means by which sub-MIC levels of 3-O-octanoyl-(−)-epicatechin induced the formation of pseudo-multicellular bacteria [cells which have divided but failed

**Figure 5** Potassium loss from populations of \(~1 \times 10^9\) CFU ml⁻¹ *Staphylococcus aureus* NCTC 6571 incubated with MIC levels of (a) 3-O-octanoyl-(−)-epicatechin, (b) novobiocin and (c) penicillin G. (▱) 1.83% (v/v) DMSO and 0.06% (w/v) sodium chloride; (△) 1.83% (v/v) DMSO and 0.06% (w/v) sodium chloride supplemented with 3-O-octanoyl-(−)-epicatechin, novobiocin or penicillin G.
to separate (Giesbrecht et al. 1998)] in the previous study (Stapleton et al. 2004) is not clear at the current time. Any damage caused to a component of the bacterium as important as the cytoplasmic membrane is likely to trigger a cascade of secondary (i.e. indirect) events though, one of which may be inhibition of cell wall autolysins. Alternatively, it could be that sub-MIC levels of 3-O-octanoyl-(−)-epicatechin induce the formation of pseudomulticellular bacteria by inhibiting cell wall autolysins directly, and that this represents an as-yet-uncharacterized activity of this compound which is separate and distinct from its cytoplasmic membrane activity.

In summary, results from the present investigation indicate that 3-O-octanoyl-(−)-epicatechin has inhibitory activity against antibiotic sensitive, β-lactam-resistant and vancomycin-resistant Gram-positive bacteria. Aggregatory studies with the semi-synthetic flavonoid failed to generate definitively negative results, but it is clear that this agent does not induce clumping of bacterial cells on the same scale as naturally occurring flavonoids such as galangin (Cushnie et al. 2007). This finding, together with data from time-kill and potassium loss assays, very strongly suggests that 3-O-octanoyl-(−)-epicatechin has bactericidal activity. Results from potassium loss assays indicate that the primary target of this agent is the cytoplasmic membrane. Further investigations are warranted to establish whether acyl catechins such as 3-O-octanoyl-(−)-epicatechin would be useful as topical therapeutic agents. Though the antibacterial activity of these compounds is only of moderate potency, future optimization through structural alteration and formulation may allow the development of a pharmacologically acceptable class of antibacterial agents. Research by Kajiya et al. (2004) and Stapleton and Taylor (unpublished results), for example, indicates that catechin activity is potentiated by the presence of sodium chloride, and synergy studies with 3-O-octanoyl-(−)-epicatechin and sodium chloride might yield a formulation with improved antibacterial activity.

Acknowledgements

The authors are very grateful to Dr Bruce Thomson and Mr John Wood for their instruction in atomic emission spectrophotometry, and Mr Brian Stewart for his assistance with the Leitz DMR microscope and DMRD camera system. Thanks also to Dr Derek Chapman and Miss Vivienne Hamilton for their advice and useful discussion.

References

Block, J.H. and Beale, J.M. (2004) Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry. London: Lippincott Williams and Wilkins.

Caturla, N., Vera-Samper, E., Villalain, I., Mateo, C.R. and Micol, V. (2003) The relationship between the antioxidant and the antibacterial properties of galloylated catechins and the structure of phospholipid model membranes. Free Radic Biol Med 34, 648–662.

Croft, A.C., D’Antoni, A.V. and Terzulli, S. (2007) Update on the antimicrobial resistance crisis. Med Sci Monit 13, 103–181.

Cushnie, T.P.T. and Lamb, A.J. (2005a) Antimicrobial activity of flavonoids. Int J Antimicrob Agents 26, 343–356.

Cushnie, T.P.T. and Lamb, A.J. (2005b) Detection of galangin-induced cytoplasmic membrane damage in Staphylococcus aureus by measuring potassium loss. J Ethnopharmacol 101, 243–248.

Cushnie, T.P.T., Hamilton, V.E.S. and Lamb, A.J. (2003) Assessment of the antibacterial activity of selected flavonoids and consideration of discrepancies between previous reports. Microbiol Res 158, 281–289.

Giesbrecht, P., Kersten, T., Maidhof, H. and Wecke, J. (1998) Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicillin. Microbiol Mol Biol Rev 62, 1371–1414.

Gould, I.M. (2005) The clinical significance of methicillin-resistant Staphylococcus aureus. J Hosp Infect 61, 277–282.

Havsteen, B.H. (2002) The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96, 67–202.

IDSA (2004) Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates. A Public Health Crisis Brews. Alexandria: Infectious Diseases Society of America.

Ikigai, H., Nakae, T., Hara, Y. and Shimamura, T. (1993) Bactericidal catechins damage the lipid bilayer. Biochim Biophys Acta 1147, 132–136.

Kajiya, K., Hojo, H., Suzuki, M., Nanjo, F., Kumazawa, S. and Nakayama, T. (2004) Relationship between antibacterial activity of (+)-catechin derivatives and their interaction with a model membrane. J Agric Food Chem 52, 1514–1519.

Mak, P., Pohl, J., Dubin, A., Reed, M.S., Bowers, S.E., Fallon, M.T. and Shafer, W.M. (2003) The increased bactericidal activity of a fatty acid-modified synthetic antimicrobial peptide of human cathpsin G correlates with its enhanced capacity to interact with model membranes. Int J Antimicrob Agents 21, 13–19.

Mellou, F., Lazari, D., Skaltsa, H., Tselpas, A.P., Kolisis, F.N. and Stamatis, H. (2005) Biocatalytic preparation of acylated derivatives of flavonoid glycosides enhances their antioxidant and antimicrobial activity. J Biotechnol 116, 295–304.
Nishino, C., Enoki, N., Tawata, S., Mori, A., Kobayashi, K. and Fukushima, M. (1987) Antibacterial activity of flavonoids against Staphylococcus epidermidis, a skin bacterium. Agric Biol Chem 51, 139–143.

Schwaber, M. J., Wright, S.B., Carmeli, Y., Venkataraman, L., DeGirolami, P.C., Gramatikova, A., Perl, T.M., Sakoulas, G. et al. (2003) Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis 9, 657–664.

Stapleton, P.D., Shah, S., Hamilton-Miller, J.M.T., Hara, Y., Nagaoka, Y., Kumagai, A., Uesato, S. and Taylor, P.W. (2004) Anti-Staphylococcus aureus activity and oxacillin resistance modulating capacity of 3-O-acyl-catechins. Int J Antimicrob Agents 24, 374–380.

Taguri, T., Tanaka, T. and Kouno, I. (2004) Antimicrobial activity of 10 different plant polyphenols against bacteria causing food-borne disease. Biol Pharm Bull 27, 1965–1969.

Taylor, P.W., Hamilton-Miller, J.M.T. and Stapleton, P.D. (2005) Antimicrobial properties of green tea catechins. Food Sci Technol Bull 2, 71–81.

Tsuchiya, H. (1999) Effects of green tea catechins on membrane fluidity. Pharmacology 59, 34–44.

Watkins, K. (2002) Fighting the clock. Chem Eng News 80, 27–33.

WHO (2003) Traditional Medicine (Fact Sheet No. 134). Geneva: World Health Organization.